ALSO NOTED: Crucell shares up on TB data; Celera, Merck ink cancer deal; and much more...

> A federal patent office may appeal a court ruling that threw out a new cap limiting the number of times a company can resubmit patent applications. That change was aggressively contested by the biopharma industry. Story

> Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. Report

> Celera has granted Merck a two-year license covering access to up to 10 cancer therapies. Release

> Bausch & Lomb has forged a deal to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases. Release

> Rep. Henry Waxman and 26 of his Congressional counterparts are wading into the compulsory licensing fray. Report

> Roche is appealing to a higher power on Mircera. Report

> What does Exubera's possible cancer link teach us about drug safety? Report

And Finally... Fuzzy-headed today? Then pop a pill. Professionals of all kinds are doing it these days, according to a survey taken by Nature. Report